Immunome Gestione

Gestione criteri di controllo 1/4

Immunome Il CEO è Clay Siegall, nominato in Oct2023, e ha un mandato di 1.08 anni. la retribuzione annua totale è $ 15.65M, composta da 1% di stipendio e 99% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.69% delle azioni della società, per un valore di $ 4.82M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.1 anni e 3.4 anni.

Informazioni chiave

Clay Siegall

Amministratore delegato

US$15.6m

Compenso totale

Percentuale dello stipendio del CEO	1.0%
Mandato del CEO	1.1yrs
Proprietà del CEO	0.7%
Durata media del management	1.1yrs
Durata media del Consiglio di amministrazione	3.4yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Clay Siegall rispetto agli utili di Immunome?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$305m
Jun 30 2024	n/a	n/a	-US$263m
Mar 31 2024	n/a	n/a	-US$232m
Dec 31 2023	US$16m	US$163k	-US$107m

Compensazione vs Mercato: La retribuzione totale di Clay ($USD 15.65M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.20M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Clay con le performance aziendali.

AMMINISTRATORE DELEGATO

Clay Siegall (63 yo)

1.1yrs

Mandato

US$15,648,944

Compensazione

Dr. Clay B. Siegall, Ph D., serves as Independent Chairman since December 13, 2023 at Tourmaline Bio, Inc. He served as Chief Executive Officer & President of Morph Immune, Inc. from March 2023 until Octob...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Clay Siegall	President	1.1yrs	US$15.65m	0.69% $ 4.8m
Jack Higgins	Chief Scientific Officer	1.1yrs	US$2.17m	0.022% $ 155.5k
Robert Lechleider	Chief Medical Officer	1.1yrs	US$3.22m	Nessun dato
Max Rosett	Executive VP of Operations	1.1yrs	Nessun dato	0.079% $ 545.8k
Philip Tsai	Chief Technical Officer	no data	Nessun dato	Nessun dato
Sandra Stoneman	Chief Legal Officer	4.1yrs	US$1.64m	0.0092% $ 63.8k
Bruce Turner	Chief Strategy Officer	1.1yrs	Nessun dato	0.070% $ 486.3k
Kinney Horn	Chief Business Officer	less than a year	Nessun dato	Nessun dato
Roee Shahar	Executive Vice President of Commercial	less than a year	Nessun dato	Nessun dato

1.1yrs

Durata media

51yo

Età media

Gestione esperta: Il team dirigenziale di IMNM non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Clay Siegall	President	1.1yrs	US$15.65m	0.69% $ 4.8m
Louis Weiner	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Philip Wagenheim	Director	6.9yrs	US$59.23k	0.65% $ 4.5m
George Prendergast	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Isaac Barchas	Lead Independent Director	1.1yrs	US$296.59k	0.0086% $ 59.7k
James Boylan	Independent Director	1.1yrs	US$294.75k	0% $ 0
Andrew Badley	Member of COVID-19 Advisory Board	3.4yrs	Nessun dato	Nessun dato
Carol Schafer	Independent Director	less than a year	Nessun dato	0% $ 0
William Strohl	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jeffrey Henderson	Member of COVID-19 Advisory Board	4.2yrs	Nessun dato	Nessun dato
Shmuel Shoham	Member of COVID-19 Advisory Board	4.2yrs	Nessun dato	Nessun dato
Susan Weiss	Member of COVID-19 Advisory Board	4.2yrs	Nessun dato	Nessun dato

3.4yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IMNM sono considerati esperti (durata media dell'incarico 3.4 anni).

Immunome Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Immunome Presents Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome, Inc. Appoints Roee Shahar as Executive Vice President, Commercial

Executive VP of Operations notifies of intention to sell stock

Immunome, Inc. to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors At the European Society for Medical Oncology Congress 2024

Consensus revenue estimates increase by 21%, EPS downgraded

Price target decreased by 8.7% to US$30.60

Immunome, Inc. Appoints Phil Tsai as Chief Technical Officer

President recently bought US$1.4m worth of stock

Consensus EPS estimates fall by 97%, revenue upgraded

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).

Immunome, Inc. Announces Promotion of Max Rosett to Chief Financial Officer

Immunome, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. Appoints Kinney Horn as Chief Business Officer

Immunome, Inc., Annual General Meeting, Jun 12, 2024

Immunome, Inc. Appoints Sandra M. Swain to Board of Directors

Consensus EPS estimates fall by 17%

Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Assets from Ayala Pharmaceuticals, Inc. (OTCPK:ADXS).

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

Immunome, Inc. has completed a Follow-on Equity Offering in the amount of $200 million.

New minor risk - Share price stability

Immunome, Inc. Announces Promotion of Max Rosett to Executive Vice President, Operations

Consensus EPS estimates upgraded to US$0.97 loss

Immunome: Why It Has Doubled Over The Last Month

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome, Inc. Announces Board Changes

Immunome, Inc. Announces Executive Changes, Effective January 2, 2024

Immunome, Inc. announced that it has received $124.722508 million in funding from Enavate Sciences, EcoR1 Capital, LLC, Redmile Group, LLC, Janus Henderson Group plc, Avidity Partners Management, L.P., Woodline Partners LP and other investors

Immunome, Inc. Appoints Jean-Jacques Bienaimé to Board of Directors

Immunome Appoints Bob Lechleider as Chief Medical Officer

Less than half of directors are independent

New major risk - Shareholder dilution

Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others for $51.7 million.

Immunome, Inc. announced that it expects to receive $124.722508 million in funding

No longer forecast to breakeven

Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?

Immunome, Inc. Announces Formation of Antibody-Drug Conjugate and T Cell Redirection Advisory Board

Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$8.50

High number of new directors

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

Forecast to breakeven in 2024

Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer

Immunome GAAP EPS of -$0.74

Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation

Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1

Immunome gains 34% after preclinical data on COVID-19 antibody

Immunome, Inc. Announces Initiation of Phase 1b Study of IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Provides Research & Development Update on Lead Oncology Candidate Targeting IL-38

Immunome, Inc. Announces Data Demonstrating COVID-19 Antibody Cocktail Potently Clears Omicron BA.1 Variant in Hamster Model and Retains Activity Against BA.2 Subvariant

Immunome, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target increased to US$33.00

We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth

Immunome, Inc. Antibody Cocktail Effective Against SARS-CoV-2 Omicron Variant in Vitro Live Virus Testing

Immunome Provides Update on Investigational New Drug Application for IMM-BCP-01 for the Treatment of COVID-19

Immunome, Inc. Expects IMM-BCP-01 Antibody Cocktail to Neutralize the SARS-CoV-2 Omicron Variant

Immunome Announces Submission of Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19

Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth

Immunome, Inc.(NasdaqCM:IMNM) dropped from Russell 3000E Growth Index

Director recently bought US$248k worth of stock

Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing

Immunome launches $27M private placement

Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?

Immunome, Inc. Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing

New 90-day high: US$39.01

Abzena Selects Immunome, Inc.’s Partner Research Organization for IMM-BCP-01

New 90-day high: US$20.24

Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares